Dr. Paulk’s lab is focused on next-generation AAV gene delivery and gene editing platforms. They are species/disease/organ/tissue/pathway/cell type/gene agnostic, working at the platform level to forge new paths engineering novel ways to make all AAV therapies cheaper, easier and faster. Dr. Paulk has developed gene therapies for numerous rare diseases and cancer, and has applied high-throughput comparative proteomic and epigenomic approaches to uncover fundamental AAV biology. Dr. Paulk sits on the Scientific Advisory Boards for Dyno Tx, CEVEC, Excision Bio, WhiteLab Genomics and Sarepta; Scientific Editorial Boards for the journals Human Gene Therapy and Gene Therapy; and currently sits on the American Society of Gene & Cell Therapy Translational Science & Product Development Committee. Paulk earned her BS in Medical Microbiology, her PhD in Viral Gene Therapy from Oregon Health & Science University, and completed her Postdoctoral Fellowship in Human Gene Therapy at Stanford University.
Jane Grogan, Graphite Bio